Compare · GILD vs MGX
GILD vs MGX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 4035.6x MGX ($45.7M).
- Over the past year, GILD is up 29.7% and MGX is down 35.4% - GILD leads by 65.1 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 3 for MGX).
- GILD has more recent analyst coverage (25 ratings vs 9 for MGX).
- Company
- Gilead Sciences Inc.
- Metagenomi Therapeutics Inc.
- Price
- $148.78+1.33%
- $1.22+0.00%
- Market cap
- $184.47B
- $45.7M
- 1M return
- +13.98%
- +0.41%
- 1Y return
- +29.69%
- -35.37%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2024
- News (4w)
- 12
- 3
- Recent ratings
- 25
- 9
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest MGX
- SEC Form 10-Q filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
- Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
- Chardan Capital Markets resumed coverage on Metagenomi Therapeutics with a new price target
- SEC Form 4 filed by Director Reid Laurence
- SEC Form 4 filed by Director Dere Willard H
- SEC Form 4 filed by Director Bjerkholt Eric
- SEC Form 4 filed by Director Eckhardt Juergen
- Chief Financial Officer Wapnick Pamela sold $3,746 worth of shares (2,884 units at $1.30), decreasing direct ownership by 1% to 208,491 units (SEC Form 4) to satisfy withholding tax